Study summary

A HER3-targeted antibody-drug conjugate delayed growth after EGFR pills stopped working

HERON-Lung01 trial (HER3 antibody-drug conjugate) · 498 people, phase 3 (interim analysis) · Published November 2026, The Lancet

8.3months without progression, vs 5.4 with chemotherapy

What was tested

Ruzaltatug rezetecan, an antibody-drug conjugate aimed at HER3, against pemetrexed and platinum chemotherapy after EGFR pills stopped working. Run in China.

What they found

What it means

Adds HER3 to TROP2 as a target for drug-carrying antibodies after resistance.

Lancet, via PubMed ↗ Trial record NCT06671379 ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.